Evidence map›Paper›PMID 38539471›Full record

ReviewCancers2024

Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-Analysis.

Mohamed Rahouma, Nathan Mynard, Massimo Baudo, Sherif Khairallah, Shaikha Al-Thani, Anas Dabsha, Shon Shmushkevich, Osama Shoeib, Mohamed Hossny, Elsayed Eldeeb and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mohamed RahoumaDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-8678-2060
Nathan MynardDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.
Massimo BaudoDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0003-3754-6704
Sherif KhairallahDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.
Shaikha Al-ThaniDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.
Anas DabshaDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.
Shon ShmushkevichDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.
Osama ShoeibDepartment of Cardiology, Tanta University, Tanta 31512, Egypt.ORCID 0000-0002-8161-1457
Mohamed HossnyDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0001-8474-8785
Elsayed EldeebE H Reliable Medical PC, Lutheran NYU Langone, New York, NY 11214, USA.
Hala AzizMedical Oncology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt.ORCID 0000-0003-4864-2224
Naglaa AbdelkarimDepartment of Medicine, Hematology and Oncology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Mario GaudinoDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0003-4680-0815
Abdelrahman MohamedSurgical Oncology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt.
Leonard GirardiDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065, USA.
Jun ZhangDivision of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66103, USA.ORCID 0000-0001-7886-6187
Luciano MuttiCenter for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.ORCID 0000-0002-1578-2637

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune-checkpoint inhibitors (ICIs) were proven effective in inducing tumor regression. However, its toxicity tends to be fatal. We sought to investigate the hospital volume/outcomes relationship. Databases were searched for studies reporting immune-checkpoint inhibitors adverse events (AEs) in patients with solid-organ malignancies. The outcomes were A) the pooled events rate (PER) of grade 5, grade 3-4, cardiac-related, and pulmonary-related AEs, and B) the assessment of the volume/outcomes relationship. One hundred and forty-seven studies met our inclusion criteria. The PER of grade 5, grade 3-4, and any-grade AEs was 2.75% (95%CI: 2.18-3.47), 26.69% (95%CI: 21.60-32.48), and 77.80% (95%CI: 70.91-83.44), respectively. The PER of pulmonary-related AEs was 4.56% (95%CI: 3.76-5.53). A higher number of annual cases per center was significantly associated with reduced grade 5 (

Indexed as

adverse eventscancercheckpoint inhibitorshospital volumeimmunotherapymeta-analysis

Identifiers

PMID38539471
PMCPMC10969050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.